Brokers Issue Forecasts for ABUS FY2029 Earnings

Arbutus Biopharma Co. (NASDAQ:ABUS) – Research analysts at HC Wainwright issued their FY2029 EPS estimates for Arbutus Biopharma in a research note issued on Wednesday, February 26th. HC Wainwright analyst E. Arce anticipates that the biopharmaceutical company will post earnings of $0.29 per share for the year. HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Arbutus Biopharma’s current full-year earnings is ($0.39) per share.

ABUS has been the subject of several other reports. JMP Securities upped their price target on shares of Arbutus Biopharma to $5.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. StockNews.com downgraded shares of Arbutus Biopharma from a “hold” rating to a “sell” rating in a report on Tuesday. Finally, Chardan Capital reiterated a “buy” rating and set a $5.00 price target (up from $4.50) on shares of Arbutus Biopharma in a report on Wednesday, November 20th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. According to MarketBeat.com, Arbutus Biopharma has a consensus rating of “Moderate Buy” and a consensus price target of $5.50.

Arbutus Biopharma Stock Performance

Shares of NASDAQ:ABUS opened at $3.44 on Thursday. The company has a fifty day moving average of $3.31 and a 200-day moving average of $3.66. The company has a market capitalization of $650.90 million, a PE ratio of -7.99 and a beta of 1.78. Arbutus Biopharma has a 52-week low of $2.30 and a 52-week high of $4.72.

Institutional Trading of Arbutus Biopharma

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Two Seas Capital LP increased its holdings in Arbutus Biopharma by 4.2% in the fourth quarter. Two Seas Capital LP now owns 8,740,956 shares of the biopharmaceutical company’s stock valued at $28,583,000 after purchasing an additional 353,568 shares during the period. Whitefort Capital Management LP increased its holdings in Arbutus Biopharma by 2.9% in the fourth quarter. Whitefort Capital Management LP now owns 13,241,916 shares of the biopharmaceutical company’s stock valued at $43,301,000 after purchasing an additional 373,949 shares during the period. Woodline Partners LP increased its holdings in Arbutus Biopharma by 45.4% in the fourth quarter. Woodline Partners LP now owns 971,628 shares of the biopharmaceutical company’s stock valued at $3,177,000 after purchasing an additional 303,475 shares during the period. Saba Capital Management L.P. increased its holdings in Arbutus Biopharma by 31.3% in the fourth quarter. Saba Capital Management L.P. now owns 887,993 shares of the biopharmaceutical company’s stock valued at $2,904,000 after purchasing an additional 211,566 shares during the period. Finally, Rafferty Asset Management LLC increased its holdings in Arbutus Biopharma by 27.6% in the fourth quarter. Rafferty Asset Management LLC now owns 146,803 shares of the biopharmaceutical company’s stock valued at $480,000 after purchasing an additional 31,782 shares during the period. 43.79% of the stock is currently owned by institutional investors and hedge funds.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.